Positive trial results for Sirtex
21 May, 2002 by Daniella GoldbergSydney-based company Sirtex Medical has completed Phase II/III clinical trials that showed over 90 per cent of liver cancer patients successfully responded to its radioactive SIR-Spheres treatment.
Virax appoints new R&D head
21 May, 2002 by Tanya HollisImmune-based therapies developer Virax Holdings (ASX: VHL) has appointed a British scientist to head its vector research and process development.
South Australian feature: Biotechnology in the field
21 May, 2002 by Melissa TrudingerThe South Australian Research and Development Institute (SARDI) is part of South Australia's Department of Primary Industries and Resources.
Solution in sight for frozen pig embryo riddle
20 May, 2002 by Pete YoungA small Australian research team believes it is poised to solve a 25-year-old riddle and open new horizons for the global pig industry.
MicroMedical loss 'expected'
17 May, 2002 by Tanya HollisArtificial heart developer MicroMedical Industries has forecast a larger full-year loss than it experienced last year, but said it was an expected outcome.
Eiffel partners with UK drug delivery specialist
17 May, 2002 by Tanya HollisMelbourne bioengineering company Eiffel Technologies has entered a research partnership with London-based Amarin Corporation to manufacture slow-release, sub-micron sized drugs.
Tasmanian feature: GM ban impacts on local bio
17 May, 2002 by Tanya Hollis and Melissa TrudingerA moratorium by the Tasmanian government on genetically modified organisms has the potential to seriously impact future biotechnology research in the state, especially in the agricultural sector.
Meditech's contribution to cancer fight
17 May, 2002 by Daniella GoldbergMeditech Research has completed Phase I clinical trials of its anti-cancer therapy HyDox, indicating the treatment is safe for patients with breast cancer, renal carcinoma, sarcoma and prostate cancer.
Ambri hopes its tech can prevent endoscopy injury
16 May, 2002 by Daniella GoldbergAmbri is looking to expand the potential applications of its critical care diagnostic system, SensiDx System, enabling surgeons to rapidly detect bowel damage that can occur during an operation.
Premier Bionics' IPO set to make target
16 May, 2002 by Tanya HollisDevice and diagnostics investment company Premier Bionics is on track to close its initial public offering tomorrow (May 17) oversubscribed.
ResMed buys motor company
16 May, 2002 by Daniella GoldbergStrengthening its foothold in the US, ResMed has acquired the Californian manufacturing company, Servo Magnetics Inc (SMI) for about $US32 million ($58.38 million).
Victorian feature: Infrastructure key to biotech success
16 May, 2002 by Tanya Hollis and Melissa TrudingerThe need to build Victoria's biotechnology infrastructure base has been recognised through the establishment of the Biotechnology Platform Technology Working Party.
Victorian feature: Smaller players face big issues
16 May, 2002 by Tanya Hollis and Melissa TrudingerWhile Victorian companies who have been around the block a few times reckon the latest batch of biotech newcomers have got it relatively easy, the feeling out there is quite different.
Clone International looks to NZ for bulls
16 May, 2002 by Melissa TrudingerClone International has crossed the Tasman in its search for elite dairy bulls. A joint venture agreement has been signed with NZ artificial breeding company Ambreed New Zealand.
Peptech wins three more US patents
15 May, 2002 by Daniella GoldbergSydney-based company Peptech has been issued three divisional applications by the US Patent and Trademarks Office in respect of its TNF antibody patent, bringing the antibody's patent tally to four.
